Cognition Therapeutics Reveals Promising Biomarker Strategy for Alzheimer's Treatment Patient Selection
Cognition Therapeutics' Phase 2 SHINE study demonstrates that Alzheimer's patients with lower p-tau217 levels showed 95% improvement on ADAS-Cog 11 and 108% better MMSE scores with zervimesine treatment versus placebo.
Prothena's Birtamimab Shows Promise in Phase 3 Trial for AL Amyloidosis with Focus on High-Risk Patients
Prothena's Phase 3 AFFIRM-AL trial evaluates birtamimab in Mayo stage 4 AL amyloidosis patients, targeting a survival benefit with a p-value threshold of 0.10 per FDA agreement.
Inhibikase Halts Parkinson's Drug Development Following Phase II Trial Setback
Inhibikase Therapeutics discontinues development of risvodetinib for Parkinson's disease after Phase II trial fails to show significant efficacy despite meeting safety endpoints.
Eisai's Leqembi Receives Positive Recommendation in Europe, Limited to Specific Genetic Profile
The European Medicines Agency's (EMA) CHMP supports Leqembi's approval for early Alzheimer's, reversing its earlier negative opinion.
Parkinson's Disease Research Focuses on Disease-Modifying Therapies
Research in the seven major markets (7MM) increasingly prioritizes disease-modifying therapies (DMTs) and treatments for non-motor symptoms of Parkinson's disease.
Parkinson's Disease Research Shifts Focus to Disease-Modifying Therapies
Clinical research in Parkinson's disease (PD) is increasingly focused on disease-modifying therapies (DMTs) to address unmet needs beyond motor symptom management.
Parkinson's Disease Research Focuses on Disease-Modifying Therapies
Clinical research in the seven major markets (7MM) for Parkinson's disease (PD) is heavily focused on disease-modifying therapies (DMTs) to address unmet needs.
Parkinson's Disease Research Focuses on Disease-Modifying Therapies
The Parkinson's disease (PD) therapeutic market faces unmet needs, notably the absence of neuroprotective/disease-modifying therapies (DMTs) and treatments for non-motor symptoms.